Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2506 to 2520 of 8221 results

  1. Lifileucel for previously treated unresectable or metastatic melanoma ID3863: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 22 January 2026.

    Technology appraisal guidance
    In consultation

  2. V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]

    Awaiting development Reference number: GID-TA11881 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400

    Awaiting development Reference number: GID-TA11509 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]

    In development Reference number: GID-TA11334 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Severe and enduring mental illness guidance review

    In development Reference number: GID-NG10465 Expected publication date: TBC

    NICE guideline
    In development

  6. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

    Quality standard
    In development

  7. Aggressive behaviour in people receiving NHS or social care

    In development Reference number: GID-QS10196 Expected publication date:  28 January 2027

    Quality standard
    In development

  8. Suspected Cancer: recognition and referral (update)

    In development Reference number: GID-NG10443 Expected publication date:  25 March 2026

    NICE guideline
    In development

  9. Aggressive behaviour in people receiving NHS or social care: prevention and management

    In development Reference number: GID-NG10432 Expected publication date:  28 January 2027

    NICE guideline
    In development

  10. Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]

    Awaiting development Reference number: GID-TA11703 Expected publication date:  21 January 2026

    Technology appraisal guidance
    Awaiting development

  11. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614]

    Awaiting development Reference number: GID-TA11811 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]

    Awaiting development Reference number: GID-TA11868 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Zuranolone for treating postnatal depression [ID6431]

    In development Reference number: GID-TA11356 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development